Home › Research › Topics › csf
csf
900 studies tagged csf, dated 1980-07-01 to 2026-10-16. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
900 studies carry this tag.
Date range
1980 to 2026
Top journals
- Neurology 132
- Alzheimer s & Dementia 37
- JAMA neurology 36
- Alzheimer's research & therapy 30
- Journal of Alzheimer's disease : JAD 30
255 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
These findings suggest EPVS burden to be a potential marker of both CSVD and AD-related BBM pathology.
-
43/100
In PD patients, a decrease in [ 18 F]DOPA PET retention correlated with disease duration as well as CSF neurodegenerative and synaptic biomarkers but not with inflammatory biomarkers or [ 18 F]RO948 PET midbrain off-target retention.
-
BackgroundAs the prevalence of Alzheimer disease (AD) rises, early identification of at-risk individuals is essential for effective intervention.
-
Mitochondrial oxidative stress and neuroinflammation are involved in the onset and progression of Alzheimer's disease (AD).
-
ε4, socioeconomic status, physical activity, smoking, subjective cognitive decline, and various cardiovascular risk factors and comorbidities.
-
Major systemic diseases elevate AMD risk, compounded by comorbidities.
-
Blood-based biomarkers hold significant promise for the early detection and diagnosis of Alzheimer’s disease (AD) and other dementias.
-
Plasma p-tau217/Aβ42 had high accuracy to detect AD, with comparable performance across race.
-
Our findings suggest that microglial and astrocyte reactivity, measured through fluid biomarkers, occur early and impact the amyloid cascade on the preclinical Alzheimer´s continuum.
-
The study included 25 patients with iCAA (age, 44±11 years), 31 patients with sCAA (age, 75±5 years), 28 patients with AD (age, 71±8 years) and 30 controls (age, 72±8 years) from 9 case descriptions and 1 cohort study.
-
A decline in TMT was associated with worse cognitive function, increased cerebral tau deposition and impaired functional performance.
-
It is largely unknown how alcohol use affects the risk of Alzheimer`s disease (AD).
-
50/100
, respectively (p-values < 0.05), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC = 0.94).
-
High Resolution Image Download MS PowerPoint Slide Responders (R) and Non-Responders (NR) to lymphatic-venous anastomosis (LVA) surgery for relief of cognitive impairment show significant difference in their p-tau181/Aβ42 ratios via enzyme-linked immunosorbent assay (ELISA) of their cerebrospinal fluid (CSF).
-
The complexity of neurodegenerative disorders necessitates an integrative approach that incorporates morphological, functional, and molecular biomarkers.
-
Recent advances in our understanding of non-cell-autonomous mechanisms in neurodegenerative diseases (NDDs) have highlighted microglial dysfunction as a core driver of disease progression.
-
Biomarkers serve as a quantitative measure of brain injury and may predict cognitive outcome after cardiac arrest.
-
A one‐point ALI increase was associated with MCI conversion odds by 15%.
-
64/100
The trajectories of core Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers and the concurrent cognitive changes across the clinical spectrum remain unclear yet are important for clinical trial design.
-
There are increasing calls for sharing individual biomarker results with participants in dementia research.
-
Plasma phosphorylated Tau217 (pTau217) demonstrated the highest diagnostic accuracy for AD, DLB, and FTD (area under the curve [AUCs]: 0.9, 0.84, and 0.79, respectively).
-
LCN2 is not only a potential biomarker for the early diagnosis of AD but may also play a significant role in the neurodegenerative processes associated with the disease.
-
Alzheimer disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia in the elderly.
-
Serum beta-synuclein level was progressively increased in the AD continuum across the preclinical, MCI and dementia stages compared with controls and was correlated with serum pTau181 (r=0.710), NfL (r=0.494) and GFAP concentrations (r=0.621, p<0.001 for all).
-
Greater neighborhood disadvantage was associated with elevated inflammatory and AD CSF biomarkers cross-sectionally and longitudinal increases in a nonspecific inflammatory blood biomarker.
-
The pTau217/Aβ42 ratio demonstrated the highest diagnostic accuracy, with an AUC of 0.927 (0.900-0.954).
-
50/100
In PD‐SCD, baseline CSF Aβ42 is associated with cognitive progression.
-
With the introduction of the new causal amyloid targeting therapies, the role of biomarker-assisted diagnosis of Alzheimer disease (AD) has received a further boost.
-
Recent studies highlight the significance of plasma phosphorylated tau proteins, neurofilament light chain, and amyloid-beta ratios as reliable biomarkers.
-
The protein composition of tear fluid (TF) reflects the severity and progression of many age-related diseases.
-
Neurofilament light chain (NfL) conventionally reflects disability worsening in multiple sclerosis (MS), but does not necessarily imply MS-specific mechanisms and could be affected by biological or pathological aging, including Alzheimer disease (AD) pathology.
-
Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear.
-
35/100
Roughly 32 million people worldwide live with Alzheimer disease, yet the vascular contributions to its progression remain incompletely mapped.
-
The defining pathological features of Alzheimer disease (AD) may also be contributing factors in other dementias.
-
Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD).
-
45/100
To investigate potential associations between cerebrospinal fluid (CSF) microplastics and Alzheimer's disease (AD) pathology or cognitive function.
-
Vascular dementia (VaD) is the second most common cause of dementia.
-
CSF and plasma SNAP25 were positively correlated, but no correlation was observed for VAMP2 in these matrices.
-
Diagnosing Atypical Parkinsonian Syndromes (APS) may be challenging due to overlapping clinical features of Parkinson's disease (PD), and the lack of pathognomonic diagnostic tests.
-
Our findings suggest that poor olfaction is associated with multiple AD-related and other neurodegenerative processes.
-
The SorLA protein, encoded by the Sortilin-related receptor 1 ( SORL1 ) gene, is a major player in Alzheimer’s disease (AD) pathophysiology.
-
In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced.
-
Neuropsychological interviews and neuroimaging techniques are traditional diagnostic methods for Alzheimer's disease (AD).
-
Lobar CMB counts and the presence of CAA were associated with downstream AD plasma biomarkers, including p-tau217 (β = 0.12 [95% CI, 0.05-0.18] and 0.29 [95% CI, 0.12-0.47], respectively), GFAP (β = 0.07 [95% CI, 0.03-0.12] and 0.20 [95% CI, 0.09-0.31], respectively), and NfL (β = 0.07 [95% CI, 0.03-0.11] and 0.16 [95% CI, 0.06-0.25], respectively) with and without the mediation of Aβ uptake on PET (indirect effect: lobar CMBs-p-tau217, 59.8% [β = 0.07 (95% CI, 0.03-0.11)]; lobar CMBs-GFAP, 49.3% [β = 0.04 (95% CI, 0.01-0.06)]; lobar CMBs-NfL, 20.9% [β = 0.01 (95% CI, 0.01-0.03)]; CAA-p-tau217, 50.9% [β = 0.15 (95% CI, 0.06-0.24)]; CAA-GFAP, 39.2% [β = 0.08 (95% CI, 0.03-0.13)]; CAA-NfL, 19.2% [β = 0.03 (95% CI, 0.01-0.05)]).
-
In 1906, Alois Alzheimer first described the neuropathological hallmarks of the disease that now bears his name.
-
However, the importance of detailed cognitive phenotyping in patients without dementia when interpreting p-tau217 results remains unclear.
-
-fold changes of 1.21, 0.57, and 4.63, respectively, compared to A-.
-
The development of more effective disease-modifying treatments for Alzheimer's disease (AD) is compromised by the lack of streamlined measures to detect and monitor the full spectrum of neurodegeneration, including white matter pathology, which begins early.
-
Alzheimer's disease (AD) is characterized by the pathological accumulation of amyloid plaques and hyperphosphorylated tau proteins, leading to disruptions in synaptic transmission and neural circuit alterations.
-
Subjective cognitive decline (SCD) is proposed as an indicator of transitional disease stage 2 in the Alzheimer's disease (AD) continuum.
From across this tag
10 of the 895 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Human Alzheimer and inflammation biomarkers after anesthesia and surgery
- Clinical and multimodal biomarker correlates of ADNI neuropathological findings
- Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
- Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset
- Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects
- Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR ‐ SB Utilizing Semi‐Mechanistic Model
- CSF biomarkers in frontotemporal lobar degeneration with known pathology
- Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution
- Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
- Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term